India Cell Therapy Market Size & Outlook, 2023-2030
India Cell Therapy Market, 2018-2030 (US$M)
Global Market
Related Markets
India cell therapy market highlights
- The India cell therapy market generated a revenue of USD 22.9 million in 2023 and is expected to reach USD 103.7 million by 2030.
- The India market is expected to grow at a CAGR of 24.1% from 2024 to 2030.
- In terms of segment, autologous therapies was the largest revenue generating therapy type in 2023.
- Autologous Therapies is the most lucrative therapy type segment registering the fastest growth during the forecast period.
Cell therapy market data book summary
| Market revenue in 2023 | USD 22.9 million |
| Market revenue in 2030 | USD 103.7 million |
| Growth rate | 24.1% (CAGR from 2023 to 2030) |
| Largest segment | Autologous therapies |
| Fastest growing segment | Autologous Therapies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Allogeneic Therapies, Autologous Therapies |
| Key market players worldwide | Novartis AG ADR, Gilead Sciences Inc, Bristol-Myers Squibb Co, Johnson & Johnson, JCR Pharmaceuticals Co Ltd, JW (Cayman) Therapeutics Co Ltd Ordinary Shares, Atara Biotherapeutics Inc, Medipost, Beiersdorf AG, Nkarta Inc Ordinary Shares |
Other key industry trends
- In terms of revenue, India accounted for 0.5% of the global cell therapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, South Korea cell therapy market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 103.7 million by 2030.
The market for cell therapy in India is witnessing rapid progress due to increasing expansions of cell therapy manufacturing facilities, coupled with growing regulatory approvals for cell therapies in the country. Moreover, the companies operating in other countries are focusing on the cell and gene therapy market in India, which is expected to strengthen the competition in the country.
For instance, in May 2023, a U.S.-based company, StemCures, announced that it would set up a manufacturing lab focusing on stem cell therapy in India. Such establishments are anticipated to propel the rivalry in the cell therapy market in India.
Furthermore, cell therapies are gaining traction in the country. They are acquiring regulatory approvals from the regulatory authority of the country. For instance, in October 2023, NexCAR19, a Chimeric Antigen Receptor T-cell (CAR-T cell) therapy, received marketing approval from the Central Drugs Standard Control Organization (CDSCO).
Key Regions:U.S., UK, Japan, South Korea, Germany
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Cell Therapy Market Scope
Cell Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Beiersdorf AG | View profile | 21,958 | Unnastrasse 48, Hamburg, Germany, 22529 | www.beiersdorf.com |
| Gilead Sciences Inc | View profile | 18,000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | www.gilead.com |
| JCR Pharmaceuticals Co Ltd | View profile | 932 | 3-19 Kasuga-cho, Ashiya, Hyogo, Japan, 659-0021 | www.jcrpharm.co.jp |
| Medipost | View profile | 51-100 | Seongnam, Kyonggi-do, South Korea, Asia | www.medi-post.com/ |
| JW (Cayman) Therapeutics Co Ltd Ordinary Shares | View profile | 398 | No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, China, People's Republic of | www.jwtherapeutics.com |
| Atara Biotherapeutics Inc | View profile | 173 | 2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, United States, 91320 | www.atarabio.com |
| Nkarta Inc Ordinary Shares | View profile | 150 | 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080 | www.nkartatx.com |
India Cell Therapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell Therapy Market Outlook will help companies and investors design strategic landscapes.
Autologous Therapies was the largest segment with a revenue share of 50.66% in 2023.
Horizon Databook has segmented the India cell therapy market based on allogeneic therapies, autologous therapies covering the revenue growth of each sub-segment from 2018 to 2030.
The market for cell therapy in India is witnessing rapid progress due to increasing expansions of cell therapy manufacturing facilities, coupled with growing regulatory approvals for cell therapies in the country. Moreover, the companies operating in other countries are focusing on the cell and gene therapy market in India, which is expected to strengthen the competition in the country.
For instance, in May 2023, a U.S.-based company, StemCures, announced that it would set up a manufacturing lab focusing on stem cell therapy in India. Such establishments are anticipated to propel the rivalry in the cell therapy market in India.
Furthermore, cell therapies are gaining traction in the country. They are acquiring regulatory approvals from the regulatory authority of the country. For instance, in October 2023, NexCAR19, a Chimeric Antigen Receptor T-cell (CAR-T cell) therapy, received marketing approval from the Central Drugs Standard Control Organization (CDSCO).
- India Cell Therapy Market Therapy Type Outlook (Revenue, USD Million , 2018-2030)
- Allogeneic Therapies
- Autologous Therapies
- India Cell Therapy Market Therapeutic Area Outlook (Revenue, USD Million , 2018-2030)
- Oncology
- Cardiovascular Disease (CVD)
- Musculoskeletal Disorders
- Dermatology
- Others
Reasons to subscribe to Cell Therapy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell Therapy Market Outlook databook
- Our clientele includes a mix of Cell Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the India Cell Therapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into India Cell Therapy Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
India Cell Therapy Market, 2018-2030 (US$M)
India cell therapy market statistics, by therapy type, 2018-2030 (US$M)
